VD-1: World's first autonomous blood drawing device
Sector: Hospital • Location: Netherlands
Source: EU Funding & Tenders Portal
~500 million blood draws are missed every year, with great consequences. The most important complication is nerve injury, occurring in approximately a million cases. Nerve injury can even lead to permanent disablement. In addition to direct complications for patients, blood drawing presents real issues for clinical laboratories. Blood drawing is the only step in the blood testing process that is
- Status
- Closed
- Sector
- Hospital, Manufacturing (Industrial)
- Location
- Netherlands
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about VD-1: World's first autonomous blood drawing device
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | ~500 million blood draws are missed every year, with great consequences. The most important complication is nerve injury, occurring in approximately a million cases. Nerve injury can even lead to permanent disablement. In addition to direct complications for patients, blood drawing presents real issues for clinical laboratories. Blood drawing is the only step in the blood testing process that is not automated. The majority of lab errors occur during the blood draw, accounting for more than an estimated 160M diagnostic errors leading to misdiagnosis and -treatment plus ~€10B in yearly costs for society. Furthermore, operational costs for laboratories are high and blood drawing personnel is difficult to find. The VD-1 can autonomously draw blood from patients. Willingness to use a device is very high. The majority of patients visiting the hospital for a blood draw are willing to try the VD-1. For laboratories, the VD-1 will reduce diagnostic errors because of standardization of the process. Moreover, labs can save on operational cost and increase capacity. The benefits are clear to our (European) potential customers, who have invested, signed letters of intent to purchase and are keen to collaborate. The technology of the VD-1 (three patents applied) consists of real-time image recognition software based on AI, tested on a vast number of images, able to create a 3D vein image despite difficult conditions. Advanced robotic positioning ensures high needle precision, impossible to achieve by a human. For ultimate safety, the needle position can be adjusted based on patient movements. The overall objectives of the BRAVE project are to optimize prototype 2 and test this optimization in the BRAVE trial, subsequently industrialize and validate the positioning system with as result the fabrication of the 0-series. |
Location
Country | Netherlands |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Manufacturing (Industrial) |
Article published date | 2026-02-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Netherlands
- OSKAR
- The NL Digital Hospital
- Rosalind Franklin Biotechnology Centre, Delft, Netherlands
- HALIX cGMP Biopharmaceutical Facility, Leiden
- Fujifilm’s Cell Culture Media Manufacturing Facility, Netherlands
- SHINE Medical Isotope Production Facility, Veendam, Netherlands
- Bristol Myers Squibb’s New CAR-T Cell Therapy Facility, Leiden, Netherlands
- Celtic Medical
